Conference Coverage

Infant anaphylaxis: Study characterizes symptoms, treatment


 

FROM ACAAI

A majority of infants who presented to the emergency department with anaphylaxis appropriately received epinephrine, with symptoms typically resolving after a single treatment dose, research findings indicate.

Given that early administration of epinephrine can be potentially lifesaving for infants with anaphylaxis, the study highlighted the real-world successes in increased uptake of treatment in this vulnerable patient population.

Most infants in the study who presented to the ED and received epinephrine were able to be discharged home after just a few hours, with only 1 out of 10 requiring hospitalization.

The study also reported that most symptoms were in the skin/mucosal, gastrointestinal, respiratory, and cardiovascular (CV) systems, providing improved characterization of anaphylaxis symptoms in the infant population.

Nearly “all episodes were triggered by food – especially egg, peanut, milk, and cashew,” commented Colleen Shannon, MD, a pediatrician at Children’s Hospital of Philadelphia, who presented the research findings at the annual meeting of the American College of Allergy, Asthma, and Immunology.

Dr. Shannon noted that despite previous research demonstrating age-based differences in the presentation of anaphylaxis, the symptomatology of anaphylaxis in infants has not been robustly characterized. Better characterization of anaphylaxis in infants with allergies may help ensure earlier and more accurate diagnosis and management, she said.

For the study, the researchers performed a retrospective chart review of 169 patients between 0 and 24 months of age (mean age, 1.0 years) who presented to the emergency department of a pediatric tertiary referral center between 2019 and 2022.

All patients in the study met diagnostic criteria for anaphylaxis. The investigators used the medical records of patients to evaluate for demographics, as well as presenting symptoms and treatment.

More than half (56.2%) of infants in the study were 12 months of age or younger, and 64.5% were male.

Nearly all (96.5%) anaphylaxis episodes presenting to the ED were triggered by food. The most common foods triggering these episodes were egg (26.6%), peanut (25.4%), milk (13.6%), and cashew (10.1%).

Most symptoms involved the skin/mucosal (97.6%) and GI (74.6%) systems, followed by respiratory (56.8%) and CV (34.3%) systems. Isolated tachycardia was recorded in 84.5% of patients with CV-related symptoms.

Epinephrine was administered to 86.4% of infants who presented to the ED with anaphylaxis. Nearly a third (30.1%) of these infants received epinephrine before arriving to the ED, and 9.5% required more than 1 dose.

The researchers also found that 10.1% of patients required hospital admission, but none had symptoms severe enough to require intensive care.

Jennifer Hoffmann, MD, an emergency medicine physician at the Lurie Children’s Hospital of Chicago, told this news organization that while characterizing anaphylaxis symptoms is relevant for clinicians, it also remains vitally important “to teach parents of infants how to recognize the signs of anaphylaxis, particularly as they begin to introduce new foods,” to ensure timely treatment.

She added that since most infants in the study improved after a single dose of epinephrine, most infants presenting to the ED with anaphylaxis can therefore be safely discharged home after only a brief period of observation. “That is, age alone should not be a reason for admission,” explained Dr. Hoffmann, who wasn’t involved in the research study.

The study was independently supported. Dr. Shannon and Dr. Hoffmann report no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Recommended Reading

AHA challenges diet doctor’s study alleging COVID vax risks
MDedge Dermatology
Presence of autoantibodies most predictive of long COVID in study
MDedge Dermatology
New study shows natural immunity to COVID has enduring strength
MDedge Dermatology
AAP approves CDC’s child/adolescent vax schedule for 2022
MDedge Dermatology
Needle-free epinephrine products could be available in 2023
MDedge Dermatology
Managing overuse of food IgE panels: Multiple approaches needed
MDedge Dermatology
Probiotic LGG doesn’t lessen eczema, asthma, or rhinitis risk by age 7
MDedge Dermatology
Introduce allergens early, say French allergists
MDedge Dermatology
When is an allergic reaction to raw plant food due to tree pollen?
MDedge Dermatology
Evusheld PrEP may protect immunocompromised patients from severe COVID-19
MDedge Dermatology